Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.

PMID:
31142661
2.

A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury.

Hoff U, Bubalo G, Fechner M, Blum M, Zhu Y, Pohlmann A, Hentschel J, Arakelyan K, Seeliger E, Flemming B, Gürgen D, Rothe M, Niendorf T, Manthati VL, Falck JR, Haase M, Schunck WH, Dragun D.

Acta Physiol (Oxf). 2019 May 11:e13297. doi: 10.1111/apha.13297. [Epub ahead of print]

PMID:
31077555
3.

Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury.

Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD.

Front Pharmacol. 2014 Sep 23;5:216. doi: 10.3389/fphar.2014.00216. eCollection 2014. Erratum in: Front Pharmacol. 2014;5:250.

4.

Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage.

Li J, Stier CT, Chander PN, Manthati VL, Falck JR, Carroll MA.

Front Pharmacol. 2014 Aug 15;5:187. doi: 10.3389/fphar.2014.00187. eCollection 2014.

5.

14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications.

Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB.

J Med Chem. 2014 Aug 28;57(16):6965-72. doi: 10.1021/jm500262m. Epub 2014 Aug 19. Erratum in: J Med Chem. 2014 Nov 13;57(21):9218. Atcha, Krishnam Raju [added].

6.

Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.

Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, Pozzi A.

J Am Soc Nephrol. 2015 Mar;26(3):597-610. doi: 10.1681/ASN.2013090980. Epub 2014 Jul 28.

7.

Effects of 5,14-HEDGE, a 20-HETE mimetic, on lipopolysaccharide-induced changes in MyD88/TAK1/IKKβ/IκB-α/NF-κB pathway and circulating miR-150, miR-223, and miR-297 levels in a rat model of septic shock.

Sari AN, Korkmaz B, Serin MS, Kacan M, Unsal D, Buharalioglu CK, Sahan Firat S, Manthati VL, Falck JR, Malik KU, Tunctan B.

Inflamm Res. 2014 Sep;63(9):741-56. doi: 10.1007/s00011-014-0747-z. Epub 2014 Jun 12.

8.

Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat.

Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD.

Hypertension. 2013 Nov;62(5):905-13. doi: 10.1161/HYPERTENSIONAHA.113.01949. Epub 2013 Aug 26.

9.

Epoxyeicosanoids promote organ and tissue regeneration.

Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13528-33. doi: 10.1073/pnas.1311565110. Epub 2013 Jul 29.

10.

20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension.

Ding Y, Wu CC, Garcia V, Dimitrova I, Weidenhammer A, Joseph G, Zhang F, Manthati VL, Falck JR, Capdevila JH, Schwartzman ML.

Am J Physiol Renal Physiol. 2013 Sep 1;305(5):F753-63. doi: 10.1152/ajprenal.00292.2013. Epub 2013 Jul 3.

11.

Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.

Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, Buharalioglu CK, Sahan-Firat S, Cuez T, Schunck WH, Manthati VL, Falck JR, Malik KU.

Nitric Oxide. 2013 Sep 1;33:18-41. doi: 10.1016/j.niox.2013.05.001. Epub 2013 May 14.

12.

Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase.

Wu CC, Mei S, Cheng J, Ding Y, Weidenhammer A, Garcia V, Zhang F, Gotlinger K, Manthati VL, Falck JR, Capdevila JH, Schwartzman ML.

J Am Soc Nephrol. 2013 Jul;24(8):1288-96. doi: 10.1681/ASN.2012070714. Epub 2013 May 2.

13.

Introgression of Brown Norway CYP4A genes on to the Dahl salt-sensitive background restores vascular function in SS-5(BN) consomic rats.

Lukaszewicz KM, Falck JR, Manthati VL, Lombard JH.

Clin Sci (Lond). 2013 Mar;124(5):333-42. doi: 10.1042/CS20120232.

14.

Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.

Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC.

J Clin Invest. 2012 Jan;122(1):178-91. doi: 10.1172/JCI58128. Epub 2011 Dec 19.

15.

Mannose-6-phosphate regulates destruction of lipid-linked oligosaccharides.

Gao N, Shang J, Huynh D, Manthati VL, Arias C, Harding HP, Kaufman RJ, Mohr I, Ron D, Falck JR, Lehrman MA.

Mol Biol Cell. 2011 Sep;22(17):2994-3009. doi: 10.1091/mbc.E11-04-0286. Epub 2011 Jul 7.

16.

20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor.

Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB.

Biochemistry. 2011 May 10;50(18):3840-8. doi: 10.1021/bi102070w. Epub 2011 Apr 15.

17.

Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs.

Liu Y, Wang R, Li J, Rao J, Li W, Falck JR, Manthati VL, Medhora M, Jacobs ER, Zhu D.

Hypertens Res. 2011 May;34(5):630-9. doi: 10.1038/hr.2011.5. Epub 2011 Feb 10.

18.

Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury.

Hoff U, Lukitsch I, Chaykovska L, Ladwig M, Arnold C, Manthati VL, Fuller TF, Schneider W, Gollasch M, Muller DN, Flemming B, Seeliger E, Luft FC, Falck JR, Dragun D, Schunck WH.

Kidney Int. 2011 Jan;79(1):57-65. doi: 10.1038/ki.2010.377. Epub 2010 Oct 20.

19.

Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists.

Nithipatikom K, Brody DM, Tang AT, Manthati VL, Falck JR, Williams CL, Campbell WB.

Cancer Sci. 2010 Dec;101(12):2629-36. doi: 10.1111/j.1349-7006.2010.01713.x. Epub 2010 Aug 27.

20.

8,9-Epoxyeicosatrienoic acid analog protects pulmonary artery smooth muscle cells from apoptosis via ROCK pathway.

Ma J, Zhang L, Li S, Liu S, Ma C, Li W, Falck JR, Manthati VL, Reddy DS, Medhora M, Jacobs ER, Zhu D.

Exp Cell Res. 2010 Aug 15;316(14):2340-53. doi: 10.1016/j.yexcr.2010.05.013. Epub 2010 May 21.

21.

Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ.

Kim DH, Vanella L, Inoue K, Burgess A, Gotlinger K, Manthati VL, Koduru SR, Zeldin DC, Falck JR, Schwartzman ML, Abraham NG.

Stem Cells Dev. 2010 Dec;19(12):1863-73. doi: 10.1089/scd.2010.0098. Epub 2010 Oct 9.

22.

20-HETE-induced nitric oxide production in pulmonary artery endothelial cells is mediated by NADPH oxidase, H2O2, and PI3-kinase/Akt.

Bodiga S, Gruenloh SK, Gao Y, Manthati VL, Dubasi N, Falck JR, Medhora M, Jacobs ER.

Am J Physiol Lung Cell Mol Physiol. 2010 Apr;298(4):L564-74. doi: 10.1152/ajplung.00298.2009. Epub 2010 Jan 8.

23.

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions.

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR.

Front Physiol. 2010 Dec 3;1:157. doi: 10.3389/fphys.2010.00157. eCollection 2010.

24.

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice.

Sodhi K, Inoue K, Gotlinger KH, Canestraro M, Vanella L, Kim DH, Manthati VL, Koduru SR, Falck JR, Schwartzman ML, Abraham NG.

J Pharmacol Exp Ther. 2009 Dec;331(3):906-16. doi: 10.1124/jpet.109.157545. Epub 2009 Aug 28.

25.

14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.

Falck JR, Kodela R, Manne R, Atcha KR, Puli N, Dubasi N, Manthati VL, Capdevila JH, Yi XY, Goldman DH, Morisseau C, Hammock BD, Campbell WB.

J Med Chem. 2009 Aug 27;52(16):5069-75. doi: 10.1021/jm900634w.

26.

Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels.

Bodiga S, Zhang R, Jacobs DE, Larsen BT, Tampo A, Manthati VL, Kwok WM, Zeldin DC, Falck JR, Gutterman DD, Jacobs ER, Medhora MM.

J Mol Cell Cardiol. 2009 Jun;46(6):978-88. doi: 10.1016/j.yjmcc.2009.01.009.

27.

Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury.

Regner KR, Zuk A, Van Why SK, Shames BD, Ryan RP, Falck JR, Manthati VL, McMullen ME, Ledbetter SR, Roman RJ.

Kidney Int. 2009 Mar;75(5):511-7. doi: 10.1038/ki.2008.600. Epub 2008 Dec 3.

28.

Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors.

Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Manthati VL, Falck JR, Miura H.

Circ Res. 2008 Jan 4;102(1):59-67. Epub 2007 Nov 1.

29.

20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells.

Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, Laniado-Schwartzman M.

J Pharmacol Exp Ther. 2008 Jan;324(1):103-10. Epub 2007 Oct 18.

PMID:
17947496

Supplemental Content

Loading ...
Support Center